trial · primary record
PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy
NSCLC (Non-small Cell Lung Cancer)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 108 |
| Primary completion | 2028-07-08 |
| Primary endpoint | Phase Ib： Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) |
| Registry ID | NCT07063329 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:57.889Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07063329
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.